Literature DB >> 11445745

Corticosteroids for septic shock.

D Annane1.   

Abstract

OBJECTIVE: To gather the data to provide a rationale for using replacement therapy with hydrocortisone in septic shock patients. DATA SOURCES: The Medline and the Cochrane Library databases. STUDY SELECTION: Studies in animals and in humans were considered when significant data were available about the mechanisms of action of corticosteroids or about their use in severe sepsis. DATA
SUMMARY: Corticosteroids were the first anti-inflammatory drugs tested in septic patients. Randomized trials clearly showed that a short course of a large dose of anti-inflammatory steroids is ineffective and potentially harmful in patients with severe sepsis. Recent demonstrations of altered hypothalamic-pituitary-adrenal axis response to septic insult have led to a reappraisal of the use of steroids in septic shock. Randomized trials in catecholamine-dependent septic shock patients strongly suggest that replacement therapy with hydrocortisone may alleviate the symptoms of systemic inflammatory response, reduce the duration of shock, and favorably affect survival.
CONCLUSIONS: Current evidence that the therapeutic interest of replacement therapy with corticosteroids increases suggests that low doses of hydrocortisone should be offered to patients with catecholamine-dependent septic shock.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445745     DOI: 10.1097/00003246-200107001-00036

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  15 in total

Review 1.  Addisonian crisis and relative adrenal failure.

Authors:  Wouter W de Herder; Aart Jan van der Lely
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

Review 2.  Is there a role for dehydroepiandrosterone replacement in the intensive care population?

Authors:  Ketan K Dhatariya
Journal:  Intensive Care Med       Date:  2003-09-03       Impact factor: 17.440

Review 3.  [The cost of sepsis].

Authors:  O Moerer; H Burchardi
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

4.  Low-dose dexamethasone prevents endotoxaemia-induced muscle protein loss and impairment of carbohydrate oxidation in rat skeletal muscle.

Authors:  Hannah Crossland; Dumitru Constantin-Teodosiu; Paul L Greenhaff; Sheila M Gardiner
Journal:  J Physiol       Date:  2010-02-22       Impact factor: 5.182

5.  Simvastatin treatment improves survival in a murine model of burn sepsis: Role of interleukin 6.

Authors:  David C Beffa; Alan J Fischman; Shawn P Fagan; Victoria F Hamrahi; Kasie W Paul; Masao Kaneki; Yong-Ming Yu; Ronald G Tompkins; Edward A Carter
Journal:  Burns       Date:  2010-12-08       Impact factor: 2.744

6.  Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channels activity.

Authors:  R d'Emmanuele di Villa Bianca; L Lippolis; G Autore; A Popolo; S Marzocco; L Sorrentino; A Pinto; R Sorrentino
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

Review 7.  Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock.

Authors:  Ineke Vanlaere; Claude Libert
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

8.  Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients.

Authors:  Andrew J Johnston; Luzius A Steiner; Mark O'Connell; Dot A Chatfield; Arun K Gupta; David K Menon
Journal:  Intensive Care Med       Date:  2003-10-29       Impact factor: 17.440

Review 9.  Epithelial transport during septic acute kidney injury.

Authors:  Eric D Morrell; John A Kellum; Kenneth R Hallows; Núria M Pastor-Soler
Journal:  Nephrol Dial Transplant       Date:  2013-12-29       Impact factor: 5.992

10.  Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage.

Authors:  Mariana Luna; Mariana Kamariski; Iliana Principi; Victoria Bocanegra; Patricia G Vallés
Journal:  Pediatr Nephrol       Date:  2020-11-17       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.